NCT07109726 2026-05-22A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsTerremoto Biosciences Inc.Phase 1/2 Recruiting205 enrolled